Dhyana

Avatar

About Dhyana

This author has not yet filled in any details.
So far Dhyana has created 23 blog entries.

New Study: PSA levels in younger men might predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk. Smarter screening strategies that can improve the accuracy of diagnosing lethal prostate cancer are urgently needed. Through a prospective study of US men, investigators from Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health have found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future risk of lethal prostate cancer later in life. Their findings suggest that screening PSA levels in men [...]

2017-12-13T13:37:22-08:00June 21st, 2016|

California HIFU and Dr. Michael Lazar Recognizes Men’s Health Month With a Look at Prostate Cancer

California HIFU and Dr. Michael Lazar are helping to recognize Men’s Health Month by providing some valuable information and resources for men on Prostate Cancer. The idea behind Men's Health Month is to heighten the awareness of preventable health problems like prostate cancer, and to encourage early detection and treatment. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Informed Decision Making According to The Center for Disease Control and Prevention (CDC) it is important for men to be aware of prostate cancer risks and to make informed decisions. This happens best when a man— [...]

2017-12-13T13:37:22-08:00June 14th, 2016|

Focal Therapy For Prostate Cancer

 Focal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate. Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed. Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary [...]

2017-12-13T13:37:22-08:00May 3rd, 2016|

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation. HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment. “The oncological results for HIFU are broadly [...]

2017-12-13T13:37:23-08:00April 26th, 2016|

New Study Reveals Prostate Cancer Metastasis Risk Higher in Some AS Patients

Metastases develop in a small proportion of patients placed on active surveillance (AS) for prostate cancer (PCa), but the risk is significantly higher in some men than others, such as those with Gleason 7 tumors, a new study found. In a study of 980 men placed on AS—769 with low-risk and 211 with intermediate-risk PCa—a team led by Laurence Klotz, MD, of Sunnybrook Health Sciences Centre in Toronto found that 30 men (3%) progressed to metastatic disease at a median of 6.3 year after diagnosis, according to study findings published in The Journal of Urology (2016;195:1409-1414). Metastases developed in 13 (10%) of 133 patients with Gleason 7 disease. Metastases occurred in 16 low-risk and 14 intermediate-risk patients, and developed in bone in 18 patients and [...]

2017-12-13T13:37:23-08:00April 13th, 2016|

HIFU San Francisco – Meet Dr. Michael Lazar

Michael J. Lazar, MD was an early user of the HIFU technology dating back to 2007.  He was credentialed as proctor in 2010 and participated in editing the user manual for the Sonablate HIFU system. Lazar trained FDA investigators on HIFU patient care and was commissioned by SonaCare Medical to proctor FDA clinical trial cases.  He has treated or been involved with over 200 patients and is also site director for SonaCare Medical’s international training site in Puerto Vallarta, Mexico. Dr. Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983.  He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Dr. Lazar is also CEO and managing director [...]

2017-12-13T13:37:23-08:00April 12th, 2016|

HIFU Center of Excellence in San Francisco

Sonablate HIFU is available now with Dr. Michael Lazar at HIFU Center of Excellence In San Francisco located in downtown San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108 HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com Physician Practicing HIFU in San Francisco: Dr. Michael Lazar See more on the HIFU Prostate Services Website.

2017-12-13T13:37:23-08:00April 12th, 2016|

Prostate cancer treatment which avoids harming sexual performance soon available on NHS

A revolutionary prostate cancer treatment which avoids harming men’s sexual performance could soon be available on the NHS. High Intensity Focused Ultrasound kills the tumour with heat without damaging healthy tissue around it. In an NHS trial led by University College Hospital, London, 625 men were treated. After five years 93% were cancer-free. Only 15% had erectile problems compared with 30 to 60% following surgery. The results were revealed to the European Association of Urology in Munich.   Read the full story ...

2016-09-23T11:30:37-07:00April 5th, 2016|

HIFU Prostate Services Expands Management Team with Chief Operating Officer

John McLean brings significant amount of experience in HIFU, operations, marketing and medical imaging. CHARLOTTE, N.C. March 9, 2016. HIFU Prostate Services, LLC, a leading provider of minimally invasive prostate cancer treatments using high intensity focused ultrasound (“HIFU”), is pleased to announce the addition of John McLean as chief operating officer. McLean brings 17 years of experience in healthcare marketing and management to HIFU Prostate Services and will be responsible for managing treatment teams, training programs and marketing initiatives. Prior to joining HIFU Prostate Services, McLean spent eight years at SonaCare Medical where he was involved in approximately 600 HIFU cases. While at SonaCare Medical, McLean served as product manager, business manager and service engineer; he brings experience in all areas of running a successful [...]

2017-12-13T13:37:23-08:00March 29th, 2016|

Prostate cancer targeted with ultrasound ‘could transform treatment’

The study - on the effectiveness of high-intensity focused ultrasound (HIFU) to treat men with localized prostate cancer - featured at the European Association of Urology Congress (EAU16) in Munich, Germany, March 11-15, 2016. Led by University College Hospital (UCH) in London, UK, the study followed 625 men between 2004-2015, who were treated in the UK and who had localized, non-metastatic tumors; the tumors were in one part of the prostate and had not spread beyond the gland. Hashim Ahmed, a consultant urological surgeon at UCH, told the meeting that 93% of patients who underwent HIFU alone to remove their prostate tumor were still cancer-free and did not need any surgery or radiotherapy 5 years after treatment. The results follow those of an earlier study [...]

2017-12-13T13:37:23-08:00March 29th, 2016|